BGNE BeiGene Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: BGNE

Price (delayed)

$219.71

Market cap

$22.94B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.49

Enterprise value

$19.67B

Highlights
The revenue has grown by 20% YoY and by 13% from the previous quarter
BeiGene's debt has decreased by 16% from the previous quarter and by 14% YoY
The net income has declined by 37% year-on-year but it is up by 7% since the previous quarter
The company's EPS fell by 23% YoY but it rose by 10% QoQ
The equity has contracted by 29% YoY and by 6% from the previous quarter
BeiGene's quick ratio has decreased by 28% YoY and by 14% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.beigene.com/
Peers: OCUP

Key stats

What are the main financial stats of BGNE
Market
Shares outstanding
104.42M
Market cap
$22.94B
Enterprise value
$19.67B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.21
Price to sales (P/S)
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.89
Earnings
Revenue
$1.42B
EBIT
-$2.01B
EBITDA
-$1.95B
Free cash flow
-$1.82B
Per share
EPS
-$1.49
Free cash flow per share
-$17.65
Book value per share
$42.18
Revenue per share
$13.72
TBVPS
$61.4
Balance sheet
Total assets
$6.38B
Total liabilities
$2B
Debt
$596.68M
Equity
$4.38B
Working capital
$3.74B
Liquidity
Debt to equity
0.14
Current ratio
3.55
Quick ratio
3.21
Net debt/EBITDA
1.68
Margins
EBITDA margin
-137.5%
Gross margin
79.8%
Net margin
-141.5%
Operating margin
-126.4%
Efficiency
Return on assets
-28.1%
Return on equity
-39.6%
Return on invested capital
-96.5%
Return on capital employed
-41%
Return on sales
-142.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BGNE stock price

How has the BeiGene stock price performed over time
Intraday
0.32%
1 week
-1.62%
1 month
1.91%
1 year
8.54%
YTD
-0.1%
QTD
-0.1%

Financial performance

How have BeiGene's revenue and profit performed over time
Revenue
$1.42B
Gross profit
$1.13B
Operating income
-$1.79B
Net income
-$2B
Gross margin
79.8%
Net margin
-141.5%
The net income has declined by 37% year-on-year but it is up by 7% since the previous quarter
BeiGene's operating income has decreased by 24% YoY but it has increased by 5% QoQ
The revenue has grown by 20% YoY and by 13% from the previous quarter
BeiGene's net margin has increased by 18% from the previous quarter but it has decreased by 14% YoY

Growth

What is BeiGene's growth rate over time

Valuation

What is BeiGene stock price valuation
P/E
N/A
P/B
5.21
P/S
16.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.89
The company's EPS fell by 23% YoY but it rose by 10% QoQ
The price to book (P/B) is 41% higher than the last 4 quarters average of 3.7 but 10% lower than the 5-year quarterly average of 5.8
The equity has contracted by 29% YoY and by 6% from the previous quarter
BGNE's price to sales (P/S) is 54% lower than its 5-year quarterly average of 34.6
The revenue has grown by 20% YoY and by 13% from the previous quarter

Efficiency

How efficient is BeiGene business performance
BeiGene's ROIC has plunged by 122% YoY and by 12% from the previous quarter
The company's return on assets fell by 21% YoY
The company's return on sales fell by 18% YoY but it rose by 17% QoQ
BGNE's return on equity is down by 16% year-on-year

Dividends

What is BGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BGNE.

Financial health

How did BeiGene financials performed over time
BeiGene's quick ratio has decreased by 28% YoY and by 14% QoQ
The current ratio is down by 25% year-on-year and by 13% since the previous quarter
BeiGene's debt is 86% less than its equity
The equity has contracted by 29% YoY and by 6% from the previous quarter
BeiGene's debt to equity has increased by 27% YoY but it has decreased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.